Is NAVB a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,936 people get NAVB articles and Market Currents by email alert.

Get email alerts on NAVB »

HEADLINES:

Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with Nordion

Business Wire (Wed, 4:30PM)
Navidea Biopharmaceuticals, Inc Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8 • 7 Comments
Navidea Biopharmaceuticals Announces First Quarter 2013 Results

Business Wire (May 8, 2013)
Companies Developing Targeted Cancer Treatments Seek Higher Profits In 2013
Teresa Dawn • Mon, May 6 • 6 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Navidea Biopharmaceuticals to Announce First Quarter 2013 Financial Results Pre-market on Wednesday, May 8, 2013

Business Wire (May 3, 2013)
Navidea Biopharmaceuticals' CEO Hosts Lymphoseek Launch Conference (Transcript)
Wed, May 1 • 7 Comments
Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek®

Business Wire (May 1, 2013)
Navidea Biopharmaceuticals to Present at the Needham 12th Annual Healthcare Conference

Business Wire (Apr 25, 2013)
Navidea Biopharmaceuticals Announces Underwritten Sale of Common Stock

Business Wire (Apr 24, 2013)
Navidea Biopharmaceuticals Announces that Results of NAV4694 Clinical Trial Published in the Journal of Nuclear Medicine

Business Wire (Apr 18, 2013)
XenoPort: A High Probablity Run-Up Trade
bsiflingtrades • Thu, Apr 18 • 4 Comments
Three Biotech Stocks With Low Price But Great Potential
Craig Keolanui • Tue, Apr 16 • 8 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
Navidea's Presentation of Top-Line Interim Analysis of Lymphoseek® Head and Neck Phase 3 Trial Selected for Investigator Award

Business Wire (Apr 11, 2013)
For Navidea, Important News Flow Ahead As Trial Results Expand Market
PropThink • Fri, Apr 5 • 9 Comments
Navidea Biopharmaceuticals Retains Stern IR for Investor Relations Services

Business Wire (Apr 5, 2013)
Navidea Biopharmaceuticals Announces Positive Top-Line Results from Interim Analysis of Lymphoseek® Phase 3 Clinical Trial in Head and Neck Cancer

Business Wire (Apr 4, 2013)
More Bio Run-Up Ideas
Alexander Maxwell • Wed, Apr 3 • 33 Comments
Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical Trial

Business Wire (Apr 3, 2013)

To learn more about Seeking Alpha Pro, click here.

For Navidea, Important News Flow Ahead As Trial Results Expand Market
PropThink • Fri, Apr 5 • 9 Comments
A Likely Turnaround And Short Squeeze For Navidea Shares
Brian L. Wilson • Mon, Mar 18 • 7 Comments
Navidea Takes A Kicking Despite Lymphoseek Approval
EP Vantage • Fri, Mar 15 • 35 Comments
A Potential Billion Dollar Business For New Cancer Diagnostic Technology Is Coming
Maxsoar • Tue, Feb 26 • 9 Comments
Navidea Will See A Nice Run-Up To Lymphoseek's PDUFA Date
Sam Quirke • Tue, Feb 5 • 6 Comments
Quality Investors Knock On Navidea's Door; Validates Lymphoseek Potential
PropThink • Thu, Jan 31 • 11 Comments
Navidea To Run Into Anticipated Lymphoseek Approval
PropThink • Thu, Jan 17 • 9 Comments
Navidea's Catalyst Will Pay Off
Basileus • Wed, Jan 16 • 8 Comments
One Biotech Making Significant Strides When It Comes To Lymph Node Discovery
Matt Schilling • Fri, Jan 4 • 23 Comments
Navidea: Unjustly Damaged By Misleading Article
Brian L. Wilson • Thu, Dec 20, 2012 • 17 Comments
Heads You Lose 40%, Tails You Lose 70% On Gamble With Navidea Shares
The GeoTeam • Wed, Dec 19, 2012 • 82 Comments
Clear Bullish Potential In Navidea's Future
Brian L. Wilson • Tue, Nov 6, 2012 • 8 Comments
Navidea: Interesting Biotech Story Gets Even More Dramatic
Mike Williams • Tue, Oct 2, 2012 • 46 Comments
Navidea Biopharmaceutical Undervalued Approaching FDA Decision
John McCoy • Mon, Sep 3, 2012 • 38 Comments
Is Navidea Biopharmaceuticals Overbought?
Nessanb • Thu, Aug 2, 2012 • 69 Comments
Navidea Biopharmaceuticals Pre-FDA Runup: Here Are The Risks
Mike Williams • Wed, Aug 1, 2012 • 11 Comments
Navidea Biopharmaceuticals, A Diamond In The Rough
John McCoy • Tue, Jul 10, 2012 • 27 Comments
Looking For An Entry Point In Navidea Biopharmaceuticals
Entry Point • Tue, Jun 19, 2012 • 18 Comments
Navidea's Share Price Could Double This Year
Ben Yoffe • Tue, May 29, 2012 • 7 Comments
5 Reasons To Buy Navidea Biopharmaceuticals
Markus Aarnio • Mon, May 21, 2012 • 5 Comments

Companies Developing Targeted Cancer Treatments Seek Higher Profits In 2013
Teresa Dawn • Mon, May 6 • 6 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
XenoPort: A High Probablity Run-Up Trade
bsiflingtrades • Thu, Apr 18 • 4 Comments
Three Biotech Stocks With Low Price But Great Potential
Craig Keolanui • Tue, Apr 16 • 8 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
More Bio Run-Up Ideas
Alexander Maxwell • Wed, Apr 3 • 33 Comments
2 Speculative Small Cap Drug Stocks Pending Key FDA Approvals
Bret Jensen • Wed, Mar 27 • 28 Comments
These 4 Biotech Stocks Have Upside, Says Burrill's Senior Analyst
Ben Yoffe • Mon, Mar 25 • 4 Comments
1 Pharmaceutical, 1 Technology And 1 Financial Stock With Recent Intensive Insider Buying
Markus Aarnio • Wed, Mar 20 • 13 Comments
Radioactive Growth In Nuclear Medicine: An Overview
Daniel Lauchheimer • Wed, Feb 27 • 16 Comments
Upcoming FDA Approval Decision Dates For Q2 2013
David Zanoni • Fri, Feb 15 • 5 Comments
3 Small Cap Radiopharmaceuticals With An Exciting 2013 Ahead
Chemistfrog • Mon, Feb 11 • 4 Comments
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
3 Biopharma Catalyst Trades To Consider For Today
Scott Matusow • Wed, Feb 6 • 28 Comments
Looking Beyond The JPM Global Healthcare Conference: More Biotech Than Meets The Eye
Nouvelle Asset Management • Tue, Jan 8 • 14 Comments
A Different Solution? Merck Teams Up With GE To Tackle Alzheimer's
Stock Traders Daily • Thu, Dec 20, 2012 • 4 Comments
4 Speculative Stocks For The Aggressive Investor In 2013
John McCoy • Mon, Dec 3, 2012 • 21 Comments
Testing, Testing: Analyst Kevin DeGeeter On 5 Good Bets In Cancer Diagnostics
Life Sciences Report • Fri, Nov 30, 2012 • 1 Comment
4 Highly Liquid Small Cap Healthcare Stocks Set For Growth
ZetaKap • Tue, Sep 4, 2012 • 3 Comments
5 Healthcare Stocks With September Catalysts
Spencer Knight • Mon, Sep 3, 2012 • 1 Comment

Navidea Biopharmaceuticals, Inc Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8 • 7 Comments
Navidea Biopharmaceuticals' CEO Hosts Lymphoseek Launch Conference (Transcript)
Wed, May 1 • 7 Comments
Navidea Biopharmaceuticals's CEO Hosts Lymphoseek FDA Approval Conference (Transcript)
Thu, Mar 14 • 6 Comments
Navidea Biopharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7 • 3 Comments
Navidea Biopharmaceuticals' CEO Presents at Citi 2013 Global Healthcare Conference (Transcript)
Tue, Feb 26 • 4 Comments
Navidea Biopharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012
Navidea Biopharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 14, 2012

Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with Nordion

Business Wire (Wed, 4:30PM)
Navidea Biopharmaceuticals Announces First Quarter 2013 Results

Business Wire (May 8, 2013)
Navidea Biopharmaceuticals to Announce First Quarter 2013 Financial Results Pre-market on Wednesday, May 8, 2013

Business Wire (May 3, 2013)
Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek®

Business Wire (May 1, 2013)
Navidea Biopharmaceuticals to Present at the Needham 12th Annual Healthcare Conference

Business Wire (Apr 25, 2013)
Navidea Biopharmaceuticals Announces Underwritten Sale of Common Stock

Business Wire (Apr 24, 2013)
Navidea Biopharmaceuticals Announces that Results of NAV4694 Clinical Trial Published in the Journal of Nuclear Medicine

Business Wire (Apr 18, 2013)
Navidea's Presentation of Top-Line Interim Analysis of Lymphoseek® Head and Neck Phase 3 Trial Selected for Investigator Award

Business Wire (Apr 11, 2013)
Navidea Biopharmaceuticals Retains Stern IR for Investor Relations Services

Business Wire (Apr 5, 2013)
Navidea Biopharmaceuticals Announces Positive Top-Line Results from Interim Analysis of Lymphoseek® Phase 3 Clinical Trial in Head and Neck Cancer

Business Wire (Apr 4, 2013)
Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical Trial

Business Wire (Apr 3, 2013)
Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

Business Wire (Apr 1, 2013)
Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)

Business Wire (Mar 27, 2013)
Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology

Business Wire (Mar 21, 2013)
Navidea Biopharmaceuticals to Hold Conference Call to Discuss Lymphoseek FDA Approval

Business Wire (Mar 13, 2013)
FDA Approves Navidea’s Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Mapping

Business Wire (Mar 13, 2013)
Navidea Announces Fourth Quarter and Full-Year 2012 Results

Business Wire (Mar 6, 2013)
Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 2013

Business Wire (Mar 4, 2013)
Navidea Biopharmaceuticals to Present at the Cowen & Company 33rd Annual Health Care Conference

Business Wire (Feb 28, 2013)
Navidea Biopharmaceuticals to Present at the Citi 2013 Global Healthcare Conference

Business Wire (Feb 19, 2013)

NAVB vs. ETF Alternatives

Company Description

Currently, there's no company description for NAVB.

Sector: Healthcare

Industry: Medical Appliances & Equipment

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 10:16 AM Navidea Biopharmaceuticals (NAVB) says it's entered into an agreement with Nordion (NDZ -1%) to produce and supply its (123) labeled I-drug NAV5001 for late-phase clinical trials. NDZ will manufacture and supply of NAV5001 clinical trial material by radiolabeling NAVB's precursor drug product with Iodine-123 to form (123)I NAV5001, and then manage the logistics and shipping arrangements to third-party clinical trial sites. The agreement could be a precursor to a commercial supply arrangement in the future. Comment! [Healthcare, Global & FX]
Wednesday, May 8, 7:02 AM Navidea Biopharmacueticals (NAVB): Q1 EPS of -$0.06 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 8, 12:05 AM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
Tuesday, May 7, 5:30 PM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
Wednesday, May 1, 9:10 AM Premarket gainers: IQNT +34%. MSPD +31%. TRLA +14%. FIRE +12%. JRCC +11%. CAAS +8%. DWA +9%. GDOT +8%. CAVM +8%. NAVB +5%.
Losers: HIMX -9%. ELGX -8%. SWI -8%. Comment! [On the Move]
Wednesday, May 1, 12:10 AM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP Comment! [Earnings]
Tuesday, April 30, 5:35 PM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP 2 Comments [Earnings]
Thursday, April 18, 2:12 PM Navidea Biopharmaceuticals (NAVB -1.5%) says results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementia demonstrated imaging characteristics nearly identical to those of an acknowledged benchmark, gold-standard amyloid imaging agent, 11C-labeled Pittsburgh Compound-B. The authors believe these results show that NAV4694 may be useful in the early and differential diagnosis of Alzheimer’s disease. Comment! [Healthcare, On the Move]
Wednesday, April 17, 5:45 PM After-hours top gainers, as of 5:15 p.m.: CONE +9%. SLCA +4%. MXIM +4%. LNC +4%. MHR +3%.
After-hours top losers: SCSS -7%. CCK -4%. SNDK -3%. NAVB -3%. EBAY -2%. Comment! [On the Move]
Tuesday, April 9, 5:56 PM After-hours top gainers, as of 5:15 p.m.: ACTS +8%. PSUN +6%. PZE +5%. PSMT +4%. NAVB +3%.
After-hours top losers: SGYP -12%. HMA -11%. SEAC -10%. RLGY -7%. THC -5%. Comment! [On the Move]
Thursday, April 4, 9:10 AM Premarket gainers: CBMX +20%. PSDV +13%. NAVB +10%. ALU +9%. ARIA +6%.
Comment! [On the Move]
Thursday, April 4, 8:20 AM Navidea Biopharmaceuticals (NAVB +7.8%) after saying that its Lymphoseek radiopharmaceutical met its primary endpoint in a Phase III trial by identifying sentinel lymph nodes in patients with squamous cell carcinoma (skin cancer) of the head or in the mouth, Until now, expensive surgery has been used. Following the results, the study's Data Safety Monitoring Committee has recommended that Navidea close the trial early. (PR) Comment! [Healthcare, On the Move]
Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
Wednesday, March 27, 12:04 PM Navidea Biopharmaceuticals (NAVB +0.8%) bucks a weak tape after saying it's commenced enrollment in Phase 2b positron emission tomography imaging studies of NAV4694, a scan for detecting cerebral-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment. The study is designed to investigate whether scan findings have the ability to distinguish between subjects with MCI who progress to Alzheimer's disease from those who do not. 1 Comment [Healthcare, On the Move]
Thursday, March 21, 9:40 AM Navidea Biopharmaceuticals' (NAVB +2.2%) Lymphoseek radiopharmaceutical for identifying tumors met the efficacy primary endpoint in two Phase III trials. Lymphoseek, which has been approved by the FDA, demonstrated its "utility and safety" in patients with breast cancer. (PR) 3 Comments [Healthcare]
Wednesday, March 13, 1:44 PM The FDA has approved Navidea Biopharmaceutical's (NAVB -7.4%) Lymphoseek injection, a radioactive imaging agent meant to help doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove the lymph nodes. The drug, which is the first new lymph-node mapping agent approved in more than 30 years, is injected into the tumor area and later, using a hand-held radiation detector, identifies lymph nodes that have taken up Lymphoseek. 8 Comments [Healthcare, On the Move]

oneotherfool
$NAVB, That 7% jump 2-min before the close is little weird! (not complaining)
Apr 16, 6:39 PM
Reply (1)

• !Report Abuse
View all 1 replies
oneotherfool: ... aaand back to where we were before the jump.
Apr 17, 1:04 PM
• !Report Abuse
Add a reply...

140 characters

oneotherfool
$NAVB CEO to provide an update of the Company and its development programs April 5 at the Future Leaders in the Biotech Industry Conference
Apr 4, 4:18 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

oneotherfool
$NAVB Price as of Thursday close 3/28/13 is $2.71 according to Nasdaq. The displayed value of $2.66 is wrong, or am I missing something?
Mar 29, 1:32 AM
Reply (1)

• !Report Abuse
View all 1 replies
oneotherfool: Fixed! thanks.
Mar 30, 1:24 AM
• !Report Abuse
Add a reply...

140 characters

zdunham
What the heck has happened to $NAVB?
Mar 25, 1:26 PM
Reply (2)

• !Report Abuse
View all 2 replies
JMattius: Hogs get slaughtered. Sell the news.
Mar 25, 2:58 PM
• !Report Abuse
oneotherfool: Good read, published today. http://seekingalpha.com/a/ruk9.
Mar 26, 5:04 AM
• !Report Abuse
Add a reply...

140 characters

zdunham
Just picked up a bunch of shares in $NAVB. Opinions anyone?
Mar 22, 2:10 PM
Reply (1)

• !Report Abuse
View all 1 replies
oneotherfool: Gets Fda approval then plunges big time! It's a weird one. Long $NAVB.
Mar 23, 8:44 AM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
why is $NAVB tanking so much after fda approval
Mar 13, 2:42 PM
Reply (15)

• !Report Abuse
View all 15 replies
Perkins Cove: ...not in anything overnight. Daytrader.
Mar 13, 5:40 PM
• !Report Abuse
LEIGHDIST: im still in amrn also waiting for nce this week hopefully, have you heard anything
Mar 14, 8:36 AM
• !Report Abuse
Add a reply...

140 characters

John McCoy
$NAVB moving higher approaching PDUFA date, targeting $4.50 by 4-30-13.
Mar 8, 6:42 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John McCoy
$NAVB up 10% this week, closing today at $3.29. Looks to be starting it's run up to PDUFA date.
Jan 31, 6:53 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John McCoy
$NAVB looking good for run into PDUFA, will be buying more on any dip under $3.
Jan 17, 7:31 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Brian L. Wilson
$NAVB hit by Seeking Alpha slam piece in early trading today. Here's that GeoTeam was manipulating the stock http://bit.ly/12BgT4y
12/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

oneotherfool
$NAVB, That 7% jump 2-min before the close is little weird! (not complaining)
Apr 16, 6:39 PM
Reply (1)

• !Report Abuse
View all 1 replies
oneotherfool: ... aaand back to where we were before the jump.
Apr 17, 1:04 PM
• !Report Abuse
Add a reply...

140 characters

oneotherfool
$NAVB Price as of Thursday close 3/28/13 is $2.71 according to Nasdaq. The displayed value of $2.66 is wrong, or am I missing something?
Mar 29, 1:32 AM
Reply (1)

• !Report Abuse
View all 1 replies
oneotherfool: Fixed! thanks.
Mar 30, 1:24 AM
• !Report Abuse
Add a reply...

140 characters

zdunham
What the heck has happened to $NAVB?
Mar 25, 1:26 PM
Reply (2)

• !Report Abuse
View all 2 replies
JMattius: Hogs get slaughtered. Sell the news.
Mar 25, 2:58 PM
• !Report Abuse
oneotherfool: Good read, published today. http://seekingalpha.com/a/ruk9.
Mar 26, 5:04 AM
• !Report Abuse
Add a reply...

140 characters

zdunham
Just picked up a bunch of shares in $NAVB. Opinions anyone?
Mar 22, 2:10 PM
Reply (1)

• !Report Abuse
View all 1 replies
oneotherfool: Gets Fda approval then plunges big time! It's a weird one. Long $NAVB.
Mar 23, 8:44 AM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
why is $NAVB tanking so much after fda approval
Mar 13, 2:42 PM
Reply (15)

• !Report Abuse
View all 15 replies
Perkins Cove: ...not in anything overnight. Daytrader.
Mar 13, 5:40 PM
• !Report Abuse
LEIGHDIST: im still in amrn also waiting for nce this week hopefully, have you heard anything
Mar 14, 8:36 AM
• !Report Abuse
Add a reply...

140 characters

sector
What is happening with NAVB why sudden drop?!
9/10/12
Reply (12)

• !Report Abuse
View all 12 replies
candigolden: new about what?
9/10/12
• !Report Abuse
Hoang6: Up 40.45% so far.
9/17/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$NAVB fail, those who listen to my show on a reg basis know I have never liked management there.
9/10/12
Reply (3)

• !Report Abuse
View all 3 replies
thsearfoss: With that said, do you see a potential opportunity if they figure this road block out?
9/11/12
• !Report Abuse
investlearner: bad me.. burned my fingers with $NAVB. lesson learned.
9/11/12
• !Report Abuse
Add a reply...

140 characters

reachmygoals1
added NAVB today. expecting approval on Monday Sept 10.
9/6/12
Reply (2)

• !Report Abuse
View all 2 replies
reachmygoals1: large blocks of buys friday sept 7, lets see if this continues into monday or halt for fda decision. good luck to all holding NAVB
9/8/12
• !Report Abuse
reachmygoals1: re: after hour action
9/8/12
• !Report Abuse
Add a reply...

140 characters

jsIRA
New buy - NAVB. in at 3.55. Pre-FDA-approval run will start soon.
8/18/12
Reply (7)

• !Report Abuse
View all 7 replies
Manuel Pastore: Stock will rally all of next week prior to the PDUFA date, now is a great entry before the run!
8/31/12
• !Report Abuse
Manuel Pastore: If approved, is definitely breaking into new, never seen highs! for the company of course.
8/31/12
• !Report Abuse
Add a reply...

140 characters

Entry Point
even as a spec play, isn't under $3.00 cheap for NAVB ?
5/2/12
Reply (1)

• !Report Abuse
View all 1 replies
Num1PeckerHead: Treat a purchase at under $3.00 as an inexpensive option ...
5/3/12
• !Report Abuse
Add a reply...

140 characters

NAVB Navidea Biopharmaceuticals

NAVB

Navidea Biopharmaceuticals